PATIENT SUPPORT MOBILE TERMS AND CONDITIONSQULIPTA (atogepant) Patient Support Program requires Consumers to enter their mobile number as a unique identifier upon registration in order to enable Two-Factor Authentication. If Consumers consent, you will also receive Qulipta Patient Support Program updates and promotional offers via text message to their mobile device. Message frequency varies and message and data rates may apply. Consumers can unsubscribe from these messages at any time by texting "STOP". Assistance can be received by texting "HELP". If you unsubscribe, you are still able to receive transactional text messages upon request; ie, Forgot Password. There is no fee charged by Qulipta Patient Support Program to receive messages. Message and data rates may apply–this can be confirmed with your mobile service provider. Charges are billed and payable to your mobile service provider or deducted from your prepaid account. Consent is not a requirement for purchase. Data obtained from you in connection with this SMS service may include your mobile phone number, your carrier's name and the date, time, and content of your messages. We may use this information to contact you and to provide the services you request from us and this information will be used in accordance with our Privacy Notice and Terms of Use. Alerts sent via SMS may not be delivered if the mobile phone is not in range of a transmission site, or if sufficient network capacity is not available at a particular time. Even within a coverage area, factors beyond the control of the wireless carrier may interfere with message delivery, including the customer's equipment, terrain, proximity to buildings, foliage, and weather. The wireless carrier does not guarantee that alerts will be delivered and will not be held liable for delayed or undelivered messages. We will not be liable for any delays in the receipt of any SMS messages as delivery is subject to effective transmission from your network operator. T-Mobile is not liable for delayed or undelivered messages. The service is available on these US carriers only: Verizon Wireless, Sprint, Nextel, Boost, T-Mobile, AT&T, Alltel, ACS Wireless, Bluegrass Cellular, Carolina West Wireless, CellCom, Cellular One of East Central Illinois (ECIT), Cincinnati Bell, Cricket, C-Spire Wireless, Duet IP (AKA Max/Benton/Albandy), Element Mobile, Epic Touch, GCI Communications, Golden State, Hawkeye (Chat Mobility), Hawkeye (NW Missouri Cellular), Illinois Valley Cellular (IVC), Inland Cellular, iWireless, Keystone Wireless (Immix/PC Management), MetroPCS, MobiPCS, Mosaic, MTPCS/Cellular One (Cellone Nation), Nex-Tech Wireless, nTelos, Panhandle Telecommunications, Pioneer, Plateau, Revol Wireless, Rina-Custer, Rina-All West, Rina-Cambridge Telecom Coop, Rina-Eagle Valley Comm, Rina-Farmers Mutual Telephone Co, Rina-Nucla Nutria Telephone Co, Rina-Silver Star, Rina-South Central Comm, Rina-Syringa, Rina-UBET, Rina-Manti, Simmetry, South Canaan/CellularOne of NEPA, Thumb Cellular, Union Wireless, United Wireless, U.S. Cellular, Viaero Wireless, Virgin Mobile, West Central Wireless (includes Five Star Wireless). IMPORTANT SAFETY INFORMATIONDo not take QULIPTA if you have had an allergic reaction to atogepant or any ingredients in QULIPTA. Before taking QULIPTA, tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. QULIPTA may affect the way other medicines work, and other medicines may affect how QULIPTA works. Your healthcare provider may need to change the dose of QULIPTA when taken with certain other medicines. QULIPTA can cause serious side effects, including:
The most common side effects of QULIPTA are nausea, constipation, and fatigue/sleepiness. These are not all the possible side effects of QULIPTA. QULIPTA is available in 10 mg, 30 mg, and 60 mg tablets. What is QULIPTA® (atogepant)?
QULIPTA is a prescription medicine used for the preventive treatment of migraine in adults. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1‑800‑FDA‑1088. If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/PatientAccessSupport to learn more. Please see full Prescribing Information, including Patient Information, for QULIPTA, and discuss with your doctor. 
This site is intended for U.S. consumers only. |